Previous Close | 89.07 |
1-Year Change | -24.32% |
6-Months Change | 19.32% |
3-Months Change | 16.78% |
Moving Avg (50d) | 82.359 |
Moving Avg (200d) | 88.293 |
ESG Rating | - |
Exchange | NASDAQ |
Market Cap. | 34.4B |
Beta (3-Years) | 1.13 |
Revenue Growth (ttm) | 21.85% |
Net Profit Margin (ttm) | 11.08% |
Return On Assets (ttm) | 5.72% |
EPS (ttm) | 0.91 |
PE Ratio (ttm) | 97.88 |
Dividend Yield | % |
Asset Description: | DexCom, Inc. |
Predicted Direction: | Buy |
Signal Strength: | Buy |
Forecast Date: | 2025-02-14 00:00:00 |
Strong Buy | ||
Buy | ||
Neutral | ||
Sell | ||
Strong Sell |
2% | 5% | 7% | 10% | 15% | 20% |
87.289 | 84.616 | 82.835 | 80.163 | 75.709 | 71.256 |
Disclaimer - Please note that the use of AI to analyse contents may occasionally generate incorrect information.
Our cutting-edge algorithms employ macroeconomic data, fundamental and technical analysis indicators to accurately predict the optimal position for short-term trading
By harnessing these signals, we power our asset allocation tools, backtesting tool and portfolio management process, ensuring maximum returns for your investments.
Sector: | Health Care |
Industry: | Life Sciences Tools & Services |
Country: | United States |
DexCom, Inc. is an American healthcare company that develops, manufactures, produces, and distributes a line of continuous glucose monitoring systems for diabetes management. It operates internationally with headquarters in San Diego, California; and has manufacturing facilities in Mesa, Arizona; Batu Kawan, Malaysia; and Athenry, Ireland. Wikipedia